PMID- 36741003
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230207
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Development and validation of a chemotherapy tolerance prediction model for 
      Chinese multiple myeloma patients: The TM frailty score.
PG  - 1103687
LID - 10.3389/fonc.2023.1103687 [doi]
LID - 1103687
AB  - OBJECTIVE: The physical fitness of older individuals is heterogeneous, making it 
      difficult to know their chemotherapy tolerance. The toxicities may offset the 
      benefits of anti-myeloma therapy in frail patients. The accurate evaluation of 
      frailty status before chemotherapy is essential. We aimed to explore the 
      applicability of the IMWG GA and develop a new frailty screening tool more 
      suitable for Chinese MM patients. CASES AND METHODS: We performed the IMWG GA and 
      the full CGA in 167 MM patients and validated the applicability of the IMWG GA to 
      chemotherapy and prognosis. The CGA domains were screened for their predictive 
      value to improve IMWG GA and develop new frailty screening tools. RESULTS: The 
      results showed that the IMWG GA had limitations in distinguishing the risk of 
      grade >/=3 adverse events (AEs) between fit and int-fit patients. Of the CGA 
      domains, TUG and MNA-SF were independent prognostic factors for grade >/=3 AEs and 
      OS and further stratified the risk of grade >/=3 AEs in the IMWG GA int-fit 
      subgroup (P< 0.05). We combined TUG and MNA-SF to construct the TM frailty score. 
      The frail subgroup had a higher proportion of adverse outcomes, a higher hazard 
      ratio (HR) in Cox regression and a higher Harrell's C-index for distinguishing 
      the risk of grade >/=3 AEs and OS than the IMWG GA frail subgroup. CONCLUSION: The 
      TM frailty score is more suitable than the IMWG GA for evaluating chemotherapy 
      tolerance and prognosis in the Chinese population.
CI  - Copyright (c) 2023 Chen, Gu, Huang, Liu, Li and Li.
FAU - Chen, Yadong
AU  - Chen Y
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Gu, Jingli
AU  - Gu J
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Huang, Beihui
AU  - Huang B
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Liu, Junru
AU  - Liu J
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, Xiaozhe
AU  - Li X
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20230120
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9895409
OTO - NOTNLM
OT  - MNA-SF
OT  - comprehensive geriatric assessment (CGA)
OT  - frailty
OT  - multiple myeloma
OT  - timed up and go test
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/02/07 06:00
MHDA- 2023/02/07 06:01
PMCR- 2023/01/01
CRDT- 2023/02/06 03:24
PHST- 2022/11/20 00:00 [received]
PHST- 2023/01/02 00:00 [accepted]
PHST- 2023/02/06 03:24 [entrez]
PHST- 2023/02/07 06:00 [pubmed]
PHST- 2023/02/07 06:01 [medline]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1103687 [doi]
PST - epublish
SO  - Front Oncol. 2023 Jan 20;13:1103687. doi: 10.3389/fonc.2023.1103687. eCollection 
      2023.